ClinicalTrials.Veeva

Menu

Efficacy of Evonail® Solution in the Prevention of Nail Damage Induced by Docetaxel in Patients With Breast Cancer. (EVONAIL)

I

Institut de Cancérologie de Lorraine

Status

Completed

Conditions

Breast Carcinoma

Treatments

Device: Placebo excipient
Device: Evonail

Study type

Interventional

Funder types

Other

Identifiers

NCT02870699
2011-A00981-40

Details and patient eligibility

About

Docetaxel is widely used in oncology for the treatment of many solid tumors. The side effects of docetaxel are many and sometimes serious. The primary toxicity of docetaxel is neutropenia. Skin and nail manifestations, frequency, the second category of adverse events after haematological adverse events.

Use of the product Evonail® was demonstrated in a patient treated by doxetaxel and having nail damage.

The purpose of this study is to confirm the effectiveness of the film-forming solution Evonail® versus a placebo on the prevention of nail damage in women with breast cancer and treated by adjuvant docetaxel.

Enrollment

50 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years old
  • Patient with breast carcinoma
  • Patients treated with adjuvant chemotherapy (FEC + 3 docetaxel +/- Herceptin®)
  • Patients who have never been treated with taxanes
  • Patients with no nail damage before starting the study
  • ECOG performance < 2
  • Ability to provide written informed consent

Exclusion criteria

  • Patient allergic to any of the treatment components
  • Use of film-forming solution, solvents or any other products applied to the fingernails (artificial nails ...) in three weeks before the first of docetaxel treatment
  • Risk of exposure to aggressive factors nail during the study
  • Using refrigerants gloves during chemotherapy treatments
  • Onychophagia
  • Presence of nail disease or a history of nail pathology (infectious and other)
  • Pregnant or breast feeding females
  • Patients whose condition is not compatible with the follow-up study

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

50 participants in 2 patient groups

ARM A
Experimental group
Description:
* Evonail film forming solution : 1 daily application on the left hand * Placebo excipient : 1 daily application on the right hand
Treatment:
Device: Evonail
Device: Placebo excipient
ARM B
Active Comparator group
Description:
* Evonail film forming solution : 1 daily application on the right hand * Placebo excipient : 1 daily application on the left hand
Treatment:
Device: Evonail
Device: Placebo excipient

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems